Clinical and in vivo PD studies using repurposed anti-diabetic medications report mixed results but suggest an overall potential modest benefit (50) in motor and cognitive symptoms with GLP-1 receptor agonists taken for at least 12 months (51). The gene discussed is GLP1R; the disease is Parkinson disease.